Article

Response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic BRAF V600E MT colon cancer patients with acquired C-MET amplification and TPM4- ALK fusion: case report and review of literature

2022-12-06

Abstract excerpt

Colorectal cancer (CRC) with BRAFV600E CRC had a relatively poor prognosis. We report the case of a 49-year-old Chinese male was diagnosed asascending colon adenocarcinoma (cT3N+?M1) with liver metastases. The patient performed next-generation sequencing(NGS) using tissue and circulating tumor DNA (ctDNA), and the results showed a BRAFV600E mutation. He received an initial combination treatment with cetuximab, dar...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f90f67c3-08c2-57f8-813c-9235e0a86f0f
DOI: 10.21203/rs.3.rs-2325340/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic BRAF V600E MT colon cancer patients with acquired C-MET amplification and TPM4- ALK fusion: case report and review of literatureDOI 10.21203/rs.3.rs-2325340/v1Read

A multiple metastatic colon cancer patient with extra-long survival and acquired BRAF mutation: case report and literature reviewSemantic proximity Read

The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study.Semantic proximity Read

FMS‐like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancerSemantic proximity Read

Durable response to third-line combination therapy in a metastatic colorectal cancer patient with BRAF V600E mutation: A case report.Semantic proximity Read

[Two Cases of Recurrent Colon Cancer with BRAF Mutation].Semantic proximity Read

Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.Semantic proximity Read

Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification.Semantic proximity Read

Association of RAS mutational status with clinical outcomes in metastatic colorectal cancer treated with trifluridine/tipiracil or regorafenib.Semantic proximity Read

[Cetuximab for patients with metastatic colorectal cancer-from the result of recent clinical trials].Semantic proximity Read

Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumabSemantic proximity Read

Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.Semantic proximity Read

Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7.Semantic proximity Read